NYSE:SQZ - SQZ Biotechnologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.33
  • Forecasted Upside: 182.90 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$13.55
▲ +0.3 (2.26%)
1 month | 3 months | 12 months
Get New SQZ Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SQZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SQZ

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$38.33
▲ +182.90% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for SQZ Biotechnologies in the last 3 months. The average price target is $38.33, with a high forecast of $40.00 and a low forecast of $37.00. The average price target represents a 182.90% upside from the last price of $13.55.
Buy
The current consensus among 4 investment analysts is to buy stock in SQZ Biotechnologies.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/12/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/11/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/7/2021Evercore ISIInitiated CoverageOutperformHigh
i
11/24/2020Stifel NicolausInitiated CoverageBuy$38.00Low
i
11/24/2020Bank of AmericaInitiated CoverageBuy$37.00Low
i
11/24/2020BTIG ResearchInitiated CoverageBuy$40.00Low
i
(Data available from 3/6/2016 forward)
SQZ Biotechnologies logo
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company's lead product candidate, SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $13.55
$12.07
$13.68

50 Day Range

MA: $22.05
$13.25
$28.97

52 Week Range

Now: $13.55
$12.07
$36.49

Volume

258,074 shs

Average Volume

190,708 shs

Market Capitalization

$336.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of SQZ Biotechnologies?

The following Wall Street sell-side analysts have issued reports on SQZ Biotechnologies in the last twelve months: Bank of America Co., BTIG Research, Evercore ISI, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for SQZ.

What is the current price target for SQZ Biotechnologies?

3 Wall Street analysts have set twelve-month price targets for SQZ Biotechnologies in the last year. Their average twelve-month price target is $38.33, suggesting a possible upside of 182.9%. BTIG Research has the highest price target set, predicting SQZ will reach $40.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $37.00 for SQZ Biotechnologies in the next year.
View the latest price targets for SQZ.

What is the current consensus analyst rating for SQZ Biotechnologies?

SQZ Biotechnologies currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SQZ will outperform the market and that investors should add to their positions of SQZ Biotechnologies.
View the latest ratings for SQZ.

What other companies compete with SQZ Biotechnologies?

How do I contact SQZ Biotechnologies' investor relations team?

SQZ Biotechnologies' physical mailing address is 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472. The company's listed phone number is 617 758 8672 and its investor relations email address is [email protected] The official website for SQZ Biotechnologies is www.sqzbiotech.com.